Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Verastem, Inc. (VSTM : NSDQ)
 
 • Company Description   
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

Number of Employees: 48

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.25 Daily Weekly Monthly
20 Day Moving Average: 1,577,543 shares
Shares Outstanding: 186.36 (millions)
Market Capitalization: $232.95 (millions)
Beta: 0.88
52 Week High: $4.94
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.87% -12.26%
12 Week 1.63% 14.22%
Year To Date -39.02% -25.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
117 KENDRICK STREET SUITE 500
-
NEEDHAM,MA 02494
USA
ph: 781-292-4200
fax: -
bsullivan@verastem.com http://www.verastem.com
 
 • General Corporate Information   
Officers
Brian Stuglik - Chief Executive Officer and Director
Daniel Paterson - President and Chief Operating Officer
Robert Gagnon - Chief Business and Financial Officer
Timothy Barberich - Director
Paul Bunn - Director

Peer Information
Verastem, Inc. (CORR.)
Verastem, Inc. (RSPI)
Verastem, Inc. (CGXP)
Verastem, Inc. (BGEN)
Verastem, Inc. (GTBP)
Verastem, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92337C104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/01/22
Share - Related Items
Shares Outstanding: 186.36
Most Recent Split Date: (:1)
Beta: 0.88
Market Capitalization: $232.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.39 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/01/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.20
Price/Cash Flow: -
Price / Sales: 63.94
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: 158.05%
vs. Previous Quarter: 376.33%
ROE
03/31/22 - -84.99
12/31/21 - -76.14
09/30/21 - -74.26
ROA
03/31/22 - -63.51
12/31/21 - -59.17
09/30/21 - -56.61
Current Ratio
03/31/22 - 6.72
12/31/21 - 5.69
09/30/21 - 8.03
Quick Ratio
03/31/22 - 6.72
12/31/21 - 5.69
09/30/21 - 8.03
Operating Margin
03/31/22 - -2,007.44
12/31/21 - -3,468.09
09/30/21 - -3,703.23
Net Margin
03/31/22 - -2,007.44
12/31/21 - -3,468.09
09/30/21 - -3,703.23
Pre-Tax Margin
03/31/22 - -2,007.44
12/31/21 - -3,468.09
09/30/21 - -3,693.59
Book Value
03/31/22 - 0.39
12/31/21 - 0.48
09/30/21 - 0.53
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.34
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 25.12
12/31/21 - 0.28
09/30/21 - 0.25
 

Powered by Zacks Investment Research ©